We could not find any results for:
Make sure your spelling is correct or try broadening your search.
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norov... HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Show more
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in...
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus...
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a...
BP plc (NYSE:BP) – BP expects weak margins in its refining business to impact its second-quarter profits by up to $700 million. The decline in refining margins, due to excess renewable...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.215 | -10.1176470588 | 2.125 | 2.135 | 1.915 | 220089 | 2.02434561 | CS |
4 | 0 | 0 | 1.91 | 2.15 | 1.83 | 340995 | 1.97574115 | CS |
12 | 0.08 | 4.37158469945 | 1.83 | 2.15 | 1.78 | 236259 | 1.95408722 | CS |
26 | 0.16 | 9.14285714286 | 1.75 | 2.15 | 1.58 | 362106 | 1.85243301 | CS |
52 | -12.72 | -86.9446343131 | 14.63 | 20.22 | 1.55 | 419774 | 4.1575164 | CS |
156 | -16.85 | -89.8187633262 | 18.76 | 24.42 | 1.55 | 216631 | 7.23002978 | CS |
260 | -16.85 | -89.8187633262 | 18.76 | 24.42 | 1.55 | 216631 | 7.23002978 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions